Evidence map›Paper›PMID 19249807›Full record

ArticleVirology2009

Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development.

Jinliang Li, Tumul Srivastava, Ravindra Rawal, Edwin Manuel, Donna Isbell, Walter Tsark, Corinna La Rosa, Zhongde Wang, Zhongqi Li, Peter A Barry and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. The first step of peptide selection in antigen presentation by MHC class I molecules.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jinliang LiDivision of Translational Vaccine Research, Fox South, 1000B, Beckman Research Institute of the City of Hope, 1500 E. Duarte Rd., Comprehensive Cancer Center, Duarte, CA 91010, USA.
Tumul Srivastava
Ravindra Rawal
Edwin Manuel
Donna Isbell
Walter Tsark
Corinna La Rosa
Zhongde Wang
Zhongqi Li
Peter A Barry
Katharine D Hagen
Jeffrey Longmate
Don J Diamond
City of Hope · USUniversity of California, Davis · US

Funding

ZONA PELLUCIDA PEPTIDES AS IMMUNOCONTRACEPTIVE ANTIGENSP51RR000169 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI HYDE, DALLAS MELVIN · 1985 to 2011
$126.2M
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Vaccine-Induced Immunity to CMVP01CA030206 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI FORMAN, STEPHEN J · 1985 to 2010
$31.8M
Peptide Vaccine To Prevent CMV Disease After HSCTR01CA077544 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI DIAMOND, DON J · 1998 to 2017
$5.6M
Evaluation of Protective CMV Vaccines in Rhesus MacaquesR01AI063356 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI BARRY, PETER A, DIAMOND, DON J · 2005 to 2014
$4.6M
CpG DNA:Epitope Fusion Peptide Conjugates as HIV VaccineR21AI062496 · NIAID · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI DIAMOND, DON J · 2005 to 2006
$467k
NCI NIH HHS CA030206PRJ3NCI NIH HHS CA077544NCI NIH HHS CA33572NCI NIH HHS P01 CA030206NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA077544NCRR NIH HHS P51 RR000169NCRR NIH HHS RR000169NIAID NIH HHS AI062496NIAID NIH HHS AI063356NIAID NIH HHS R01 AI063356NIAID NIH HHS R21 AI062496
6 · The paper itself

Abstract

We have developed a murine model expressing the rhesus macaque (RM) Mamu-A01 MHC allele to characterize immune responses and vaccines based on antigens of importance to human disease processes. Towards that goal, transgenic (Tg) mice expressing chimeric RM (alpha1 and alpha2 Mamu-A01 domains) and murine (alpha3, transmembrane, and cytoplasmic H-2K(b) domains) MHC Class I molecules were derived by transgenesis of the H-2K(b)D(b) double MHC Class I knockout strain. After immunization of Mamu-A01/K(b) Tg mice with rVV-SIVGag-Pol, the mice generated CD8(+) T-cell IFN-gamma responses to several known Mamu-A01 restricted epitopes from the SIV Gag and Pol antigen sequence. Fusion peptides of highly recognized CTL epitopes from SIV Pol and Gag and a strong T-help epitope were shown to be immunogenic and capable of limiting an rVV-SIVGag-Pol challenge. Mamu-A01/K(b) Tg mice provide a model system to study the Mamu-A01 restricted T-cell response for various infectious diseases which are applicable to a study in RM.

Indexed as

AIDS VaccinesAnimalsCD8-Positive T-LymphocytesCell LineEpitopes, T-LymphocyteFemaleGenes, MHC Class IHistocompatibility Antigens Class IHIVMacaca mulattaMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicModels, AnimalSimian Immunodeficiency VirusAIDS VaccinesEpitopes, T-LymphocyteHistocompatibility Antigens Class IMamu-A 01 antigenVaccines, Synthetic

Identifiers

PMID19249807
PMCPMC2667874
OpenAlexW2020518826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.